Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China

Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China

Abstract Background Lorlatinib, a third-generation Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKI), has demonstrated excellent curative effect in clinical studies to overcome mutations resistant to first- and second-generation ALK-TKIs. It also has improved blood-brain barrier cros...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhujun Chen, Chunlan Tang, Xiangyu Ma, Panwen Tian, Liang Gong
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Cancer
Subjects:
ALK+
NSCLC
Lorlatinib
China
Real-world
Online Access:https://doi.org/10.1186/s12885-025-14631-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items